Please assess the completion status of the following clinical trial:

Trial Title: Study With Wee-1 Inhibitor AZD1775 (MK-1775) and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytological proof of epithelial ovarian cancer, and proven p53 mutated pathway by PCR/Sequencing. IHC will also be performed. In the additional safety and efficacy cohort also inclusion of NSCLC, SCLC, cervical and endometrial cancer (only ovarian cancer cohort is pursued)~* Measurable disease on a CT-scan or elevated Cancer Antigen (CA)-125 levels that can be monitored.~* Patients previously received standard 1st line platinum therapy (combined with paclitaxel) for epithelial ovarian cancer, and showed recurrence on or within 3 months of this treatment (relapse within 6 months in the additional safety and efficacy cohort)~* Able and willing to voluntarily give written informed consent.~* Able and willing to undergo blood sampling for pharmacokinetics and pharmacodynamics.~* Life expectancy ≥ 3 months allowing adequate follow up of toxicity evaluation and anti-tumor activity.~* Minimal acceptable safety laboratory values:~  * Absolute neutrophil count (ANC) of ≥ 1.5 x 109 /L (or 1500/m3).~ * Platelet count of ≥ 100 x 109 /L (or 100,000/mm3).~ * Hemoglobin ≥ 5.6 mmol/L (or 9.1 g/dl).~ * Hepatic function as defined by serum bilirubin ≤ 1.5 x ULN, ALAT and ASAT ≤ 2.5 x ULN, or ALAT and ASAT ≥ 5x ULN in case of liver metastases.~ * Renal function as defined by serum creatinine ≥ 1.5 x ULN or creatinine clearance ≥ 60 ml/min for patients with creatinine levels ≥ 1.5 x ULN (by Cockcroft-Gault formula).~* WHO performance status of ≤ 2 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.~* No radio- or chemotherapy within the last 4 weeks prior to study entry (palliative limited radiation for pain reduction is allowed)~* Able and willing to swallow oral medication.~* Able and willing to receive iv medication.~* Negative pregnancy test (urine/serum) for female patients with childbearing potential.~Exclusion Criteria:~* Symptomatic cerebral or leptomeningeal metastases.~* Current participation or previous participation in a study with an investigational compound, or chemo- and/or radiotherapy within 28 days of receiving first dose of study medication. (Palliative limited radiation for pain reduction is allowed only between day 8 and day 21 of the study, and allowed to a limited area to palliate pain.~* No prior radiation therapy to more than 30% of the bone marrow and patient must have recovered for at least 3 weeks from the hematologic toxicity of prior radiotherapy.~* More than 1 prior cytotoxic chemotherapy regimen in initial trial. In the additional safety and efficacy cohort: more than 2 prior cytotoxic chemotherapy regimens.~* Prior stem cell or bone marrow transplant.~* Unresolved (\> grade 1) toxicities of previous chemotherapy, excluding alopecia.~* Known hypersensitivity to the components of the combination study therapy or its analogs.~* Patient has had prescription or non-prescription drugs or other products known to be metabolized by CYP3A4, or to inhibit or induce CYP3A4 that cannot be discontinued prior to Day 1 of dosing and withheld throughout the study until 2 days after the last dose of study medication~* Bowel obstructions or motility disorders that may negatively affect oral drug absorption.~* Patients with known alcoholism, drug addiction and/or a history of psychotic disorders who are not suitable for adequate follow up.~* Women who are pregnant or breast feeding.~* Fertile women who do not agree to use a reliable contraceptive method throughout the study.~* Uncontrolled infectious disease or known Human Immunodeficiency Virus HIV-1 or HIV-2 type patients.~* Patients with a known history of hepatitis B or C.~* Neurological disease that may render a patient at increased risk for peripheral or central neurotoxicity.~* Clinical history suggestive for Li Fraumeni syndrome.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MK-1775 and carboplatin (Type: EXPERIMENTAL): MK-1775: oral capsules. Carboplatin: intravenous infusion in 30 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).